HALO - Halozyme Therapeutics, Inc. Company Long-Term Liabilities

Public company logo of Halozyme Therapeutics, Inc. (HALO)

Monitoring the long-term liabilities of Halozyme Therapeutics (HALO) demonstrates borrowing dynamics, where the 1.79 mark records this indicator. Halozyme Therapeutics (HALO) is implementing eco-friendly drug delivery methods to reduce medical waste. The strategy is based on bioethics and resource optimization in the creation of oncology drugs. Business growth relies on the active licensing of unique delivery patents through partnerships with pharmaceutical behemoths.

halozyme.com (HALO) Company Long-Term Debt: for the period 07/04/2022 - 11/01/2026

Halozyme Inc. (HALO) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price halozyme.com|HALO - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Halozyme|HALO - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Halozyme|HALO - Company Book Value|Market Value to Book Value halozyme.com|HALO - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Halozyme Therapeutics|HALO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Halozyme Corp|HALO - Company Total Debt|Debts to Book Capitalization Halozyme|HALO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Halozyme|Immediate Liquidity halozyme.com
- earnings and market multiples details:
HALO - Net Profit
Fundamental company valuation:HALO (halozyme.com)
Brand item of Halozyme Therapeutics

Long-term debt reflects the total financial obligations of the company with a maturity of more than one year. This indicator captures the actual volume of borrowed capital, forming a credit load curve on the issuer's long-term liabilities chart. Analyzing this trend allows for an assessment of balance sheet stability and the deleveraging strategy. For Halozyme Therapeutics (HALO), such funds may be directed toward the robotization of ENHANZE platform implementation processes, reducing manual labor during formula adaptation.

Competitors of Halozyme Therapeutics (HALO)

ONC: Company Long-Term Indebtedness|Revolution Medicines, Inc. - Company Long-Term Debts|Ascentage Pharma Group International (AAPG) - Company Long-Term Liabilities|CGON: Company Long-Term Debts|Long-Term Debt UroGen Pharma Corp (URGN)|Company Long-Term Debt Bicara Therapeutics Inc.|PSNL: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities ERAS (Erasca)|DCTH (Delcath Systems Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts YMAB (YmAbs)|AURA - Company Long-Term Liabilities|CADL: Company Long-Term Liabilities|ARAY - Company Long-Term Debts|sellaslifesciences.com (SLS) - Company Long-Term Debt|Actuate Therapeutics Inc. - Company Long-Term Loans and Borrowings|CTOR (Citius Oncology, Inc) - Company Long-Term Debts|Long-Term Debt TuHURA HURA|Company Long-Term Debts TARA|FATE (fatetherapeutics.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts WHWK (Aadi Bioscience)|Company Long-Term Debts TScan Therapeutics Inc TCRX|CSBR - Company Long-Term Debt|XBIT: Company Long-Term Debt|cel-sci.com (CVM) - Company Long-Term Debt|Long-Term Debt ostherapies.com (OSTX)|Company Long-Term Liabilities RADX|Artiva - Long-Term Liabilities|Company Long-Term Liabilities ANL (Adlai Nortye Ltd.)|VERU - Long-Term Debt|Company Long-Term Debt Tempest Therapeutics TPST|XLO - Company Long-Term Liabilities|Enochian BioSciences - Company Long-Term Debts|Long-Term Debt Mural Oncology plc|KAPA (kairospharma.com) - Company Long-Term Liabilities|OnKure Therapeutics - Company Long-Term Loans and Borrowings|Company Long-Term Liabilities GDTC|CRIS (Curis Corp) - Amount of Long-Term Liabilities|Company Long-Term Debts APLM|THAR (Tharimmune Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts ADVB (Advanced Biomed)|Genprex Inc (GNPX) - Long-Term Debt|CLDI - Company Long-Term Debt|Company Long-Term Loans and Borrowings SBFM (Sunshine Biopharma Inc.)|XBIO: Company Long-Term Debts|Salarius Pharmaceuticals Inc (SLRX) - Company Long-Term Debts|Company Long-Term Debt Purple Biotech Corp|AON - Long-Term Liabilities|Company Long-Term Debts BGNE|CKPT - Long-Term Debt|Elevation Oncology, Inc. - Company Long-Term Liabilities|Company Long-Term Debts iCAD Inc. ICAD|IKNA: Company Long-Term Liabilities|Notable Labs Corp - Amount of Long-Term Liabilities|VIRX: Company Long-Term Debts|MOR - Long-Term Debt Volume|NAYA (NAYA Biosciences Inc.) - Company Long-Term Debts|Company Long-Term Liabilities Ascentage Pharma Group International (AAPGV)